'We're Pretty Cheap At The Moment' - Cybin CEO Doug Drysdale
Cybin CEO Doug Drysdale talks to Jason Najum about treating mental health disorders with psychedelics and attracting new buyers with its stock price.
What Western medicine can learn from the ancient history of psychedelics
After more than 10,000 years of use, the ancient cultures and indigenous communities who use plant medicines may hold lessons ...
MDMA Therapy For PTSD Faces FDA Delay: Are There Other Ways Forward?
The U.S. Food and Drug Administration (FDA) has issued a complete response letter for MDMA-assisted psychotherapy (MDMA-AT) ...
Boing Boing on MSN3d
Ancient psychedelic wisdom for modern medicine
There's a psychedelic Renaissance underway as psychoactive substances like psilocybin, DMT, and MDMA are making headway into ...
GLP-1 hybrid drug being tested as weight-loss aid
The manufacturer of Ozempic is testing amycretin, an experimental weight-loss pill that appears to help people quickly shed ...
Mena FN19h
Investornewsbreaks Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) Completes 38-For-1 Share Consolidation
The company is currently developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder and CYB004, a proprietary deuterated DMT molecule for generalized ...
Psychedelicnewsbreaks Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) Announces Participation At The 27Th Annual Milken Institute Global Conference
Cybin (NYSE American: CYBN) (Cboe CA: CYBN) , a clinical-stage biopharmaceutical company developing new and innovative next-generation psychedelic- ...
Cybin to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) ("Cybin" or the "Company"), a clinical-stage breakthrough neuropsychiatry ...